Therapeutic potential of RNA interference against cellular targets of HIV infection

Molecular Biotechnology

Volumn 37, Issue 3, 2007, Pages 225-236

  Zhang, Jia ^a,b   Wu, Y O ^b   Xiao, Li ^b   Li, Kai ^b,c   Chen, L L ^c   Sirois, P ^d  

^a GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^b SUZHOU UNIVERSITY   (China)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Cellular target; HIV infection; RNA interference; SiRNA

Indexed keywords

DISEASES; DRUG PRODUCTS; PROTEINS; VIRUSES;

CELLULAR TARGETS; HIV INFECTION; RNA INTERFERENCE;

RNA;

CELL PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CYTOTOXICITY; DRUG MECHANISM; GENE SILENCING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; REVIEW; RNA INTERFERENCE; VIRUS ASSEMBLY; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; GENE TARGETING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, VIRAL; HIV INFECTIONS; HUMANS; MODELS, BIOLOGICAL; RNA INTERFERENCE; RNA, SMALL INTERFERING; SUBSTRATE SPECIFICITY;

EID: 36949039935     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12033-007-9000-0     Document Type: Review

References (83)

1. Glaser, S., Anastassiadis, K., & Stewart, A. F. (2005). Current issues in mouse genome engineering. Nature Genetics, 37, 1187-1193.
2. Chatterjee-Kishore, M., & Miller, C. P. (2005). Exploring the sounds of silence: RNAi-mediated gene silencing for target identification and validation. Drug Discovery Today, 10, 1559-1565.
3. Collier, L. S., & Largaespada, D. A. (2006). Transforming science: Cancer gene identification. Current Opinion in Genetics & Development, 16, 23-29.
4. Cullen, B. R. (2005). Does RNA interference have a future as a treatment for HIV-1 induced disease? AIDS Reviews, 7, 22-25.
5. Labialle, S., Dayan, G., Michaud, M., Barakat, S., Rigal, D., & Baggetto, L. G. (2005). Gene therapy of the typical multidrug resistance phenotype of cancers: A new hope? Seminars in Oncology, 32, 583-590.
6. Lovett-Racke, A. E., Cravens, P. D., Gocke, A. R., Racke, M. K., & Stuve, O. (2005). Therapeutic potential of small interfering RNA for central nervous system diseases. Archives in Neurology, 62, 1810-1813.
7. Wiznerowicz, M., & Trono, D. (2005). Harnessing HIV for therapy, basic research and biotechnology. Trends Biotechnology, 23, 42-47.
8. Colbere-Garapin, F., Blondel, B., Saulnier, A., Pelletier, I., & Labadie, K. (2005). Silencing viruses by RNA interference. Microbes and Infection, 7, 767-775.
9. Gadkari, D. A. (2005). RNA interference & inhibition of viruses. Indian Journal of Medical Research, 121, 147-150.
10. Voinnet, O. (2005). Induction and suppression of RNA silencing: Insights from viral infections. Nature Review Genetics, 6, 206-220.
11. Ryther, R. C., Flynt, A. S., Phillips, J. A., III, & Patton, J. G. (2005). siRNA therapeutics: Big potential from small RNAs. Gene Therapy, 12, 5-11.
12. Tan, F. L., & Yin, J. Q. (2004). RNAi, a new therapeutic strategy against viral infection. Cell Research, 14, 460-466.
13. Berkhout, B. (2004). RNA interference as an antiviral approach: Targeting HIV-1. Current Opinion in Molecular Therapeutics, 6, 141-145.
14. Boden, D., Pusch, O., & Ramratnam, B. (2004). HIV-1-specific RNA interference. Current Opinion in Molecular Therapeutics, 6, 373-380.
15. Chen, J. J., Zhu, Z., Gershon, A. A., & Gershon, M. D. (2004). Mannose 6-phosphate receptor dependence of varicella zoster virus infection in vitro and in the epidermis during varicella and zoster. Cell, 119, 915-926.
16. Deng, Z., Atanasiu, C., Burg, J. S., Broccoli, D., & Lieberman, P. M. (2003). Telomere repeat binding factors TRF1, TRF2, and hRAP1 modulate replication of Epstein-Barr virus OriP. Journal of Virology, 77, 11992-12001.
17. Gaggar, A., Shayakhmetov, D. M., & Lieber, A. (2003). CD46 is a cellular receptor for group B adenoviruses. Nature Medicine, 9, 1408-1412.
18. Gao, X., Wang, H., & Sairenji, T. (2004). Inhibition of Epstein-Barr virus (EBV) reactivation by short interfering RNAs targeting p38 mitogen-activated protein kinase or c-myc in EBV-positive epithelial cells. Journal of Virology, 78, 11798-11806.
19. Goh, P. Y., Tan, Y. J., Lim, S. P., Tan, Y. H., Lim, S. G., Fuller-Pace, F., et al. (2004). Cellular RNA helicase p68 relocalization and interaction with the hepatitis C virus (HCV) NS5B protein and the potential role of p68 in HCV RNA replication. Journal of Virology, 78, 5288-5298.
20. Kariko, K., Bhuyan, P., Capodici, J., Ni, H., Lubinski, J., Friedman, H., & Weissman, D. (2004). Exogenous siRNA mediates sequence-independent gene suppression by signaling through toll-like receptor 3. Cells Tissues Organs, 177, 132-138.
21. Lavillette, D., Tarr, A. W., Voisset, C., Donot, P., Bartosch, B., Bain, C., et al. (2005). Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology, 41, 265-274.
22. Nekhai, S., & Jerebtsova, M. (2006). Therapies for HIV with RNAi. Current Opinion in Molecular Therapeutics, 8, 52-61.
23. Ni, Q., Chen, Z., Yao, H. P., Yang, Z. G., Liu, K. Z., & Wu, L. L. (2004). Inhibition of human La protein by RNA interference downregulates hepatitis B virus mRNA in 2.2.15 cells. World Journal of Gastroenterology, 10, 2050-2054.
24. Sun, X., Yau, V. K., Briggs, B. J., & Whittaker, G. R. (2005). Role of clathrin-mediated endocytosis during vesicular stomatitis virus entry into host cells. Virology, 338, 53-60.
25. Wang, C., Gale, M., Jr., Keller, B. C., Huang, H., Brown, M. S., Goldstein, J. L., et al. (2005). Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Molecular Cell, 18, 425-434.
26. Wong, S. K., & Lazinski, D. W. (2002). Replicating hepatitis delta virus RNA is edited in the nucleus by the small form of ADAR1. Proceedings of the National Academy of Science of the United States of America, 99, 15118-15123.
27. Zhang, J., Yamada, O., Sakamoto, T., Yoshida, H., Iwai, T., Matsushita, Y., et al. (2004). Down-regulation of viral replication by adenoviral-mediated expression of siRNA against cellular cofactors for hepatitis C virus. Virology, 320, 135-143.
28. Zhang, T., Lin, R. T., Li, Y., Douglas, S. D., Maxcey, C., Ho, C., et al. (2005). Hepatitis C virus inhibits intracellular interferon alpha expression in human hepatic cell lines. Hepatology, 42, 819-827.
29. Zhen, Z., Bradel-Tretheway, B., Sumagin, S., Bidlack, J. M., & Dewhurst, S. (2005). The human herpesvirus 6 G protein-coupled receptor homolog U51 positively regulates virus replication and enhances cell-cell fusion in vitro. Journal of Virology, 79, 11914-11924.
30. Nguyen, D. G., Wolff, K. C., Yin, H., Caldwell, J. S., & Kuhen, K. L. (2006). "UnPAKing" human immunodeficiency virus (HIV) replication: Using small interfering RNA screening to identify novel cofactors and elucidate the role of group I PAKs in HIV infection. Journal of Virology, 80, 130-137.
31. Bucher, E., Hemmes, H., de Haan, P., Goldbach, R., & Prins, M. (2004). The influenza A virus NS1 protein binds small interfering RNAs and suppresses RNA silencing in plants. Journal of General Virology, 85, 983-991.
32. Delgadillo, M. O., Saenz, P., Salvador, B., Garcia, J. A., & Simon-Mateo, C. (2004). Human influenza virus NS1 protein enhances viral pathogenicity and acts as an RNA silencing suppressor in plants. Journal of General Virology, 85, 993-999.
33. Li, H., Li, W. X., & Ding, S. W. (2002). Induction and suppression of RNA silencing by an animal virus. Science, 296, 1319-1321.
34. Li, W. X., Li, H., Lu, R., Li, F., Dus, M., Atkinson, P., et al. (2004). Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing. Proceedings of the National Academy of Science of the United States of America, 101, 1350-1355.
35. Lu, S., & Cullen, B. R. (2004). Adenovirus VA1 noncoding RNA can inhibit small interfering RNA and MicroRNA biogenesis. Journal of Virology, 78, 12868-12876.
36. Schwartz, M., Chen, J., Janda, M., Sullivan, M., den Boon, J., & Ahlquist, P. (2002). A positive-strand RNA virus replication complex parallels form and function of retrovirus capsids. Molecular Cell, 9, 505-514.
37. Kreuze, J. F., Savenkov, E. I., Cuellar, W., Li, X., & Valkonen, J. P. (2005). Viral class 1 RNase III involved in suppression of RNA silencing. Journal of Virology, 79, 7227-7238.
38. Das, A. T., Brummelkamp, T. R., Westerhout, E. M., Vink, M., Madiredjo, M., Bernards, R., et al. (2004). Human immunodefi-ciency virus type 1 escapes from RNA interference-mediated inhibition. Journal of Virology, 78, 2601-2605.
39. Westerhout, E. M., Ooms, M., Vink, M., Das, A. T., & Berkhout, B. (2005). HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Research, 33, 796-804.
40. Wilson, J. A., & Richardson, C. D. (2005). Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. Journal of Virology, 79, 7050-7058.
41. Wu, H. L., Huang, L. R., Huang, C. C., Lai, H. L., Liu, C. J., Huang, Y. T., et al. (2005). RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. Gastroenterology, 128, 708-716.
42. Dunn, S. J., Khan, I. H., Chan, U. A., Scearce, R. L., Melara, C. L., Paul, A. M., et al. (2004). Identification of cell surface targets for HIV-1 therapeutics using genetic screens. Virology, 321, 260-273.
43. Liu, S., Asparuhova, M., Brondani, V., Ziekau, I., Klimkait, T., & Schumperli, D. (2004). Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A. Nucleic Acids Research, 32, 3752-3759.
44. Lusso, P. (2006). HIV and the chemokine system: 10 years later. The EMBO Journal, 25, 447-456.
45. Wells, T. N., Power, C. A., Shaw, J. P., & Proudfoot, A. E. (2006). Chemokine blockers - therapeutics in the making? Trends in Pharmacological Sciences, 27, 41-47.
46. Martinez, M. A., Gutierrez, A., Armand-Ugon, M., Blanco, J., Parera, M., Gomez, J., et al. (2002). Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS, 16, 2385-2390.
47. Ji, J., Wernli, M., Klimkait, T., & Erb, P. (2003). Enhanced gene silencing by the application of multiple specific small interfering RNAs. FEBS Letters, 552, 247-252.
48. Lee, M. T., Coburn, G. A., McClure, M. O., & Cullen, B. R. (2003). Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. Journal of Virology, 77, 11964-11972.
49. Anderson, J., & Akkina, R. (2005). HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector. AIDS Research and Therapy, 2, 1.
50. Anderson, J., Banerjea, A., & Akkina, R. (2003). Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance. Oligonucleotides, 13, 303-312.
51. Arrighi, J. F., Pion, M., Wiznerowicz, M., Geijtenbeek, T. B., Garcia, E., Abraham, S., et al. (2004). Lentivirus-mediated RNA interference of DC-SIGN expression inhibits human immunodeficiency virus transmission from dendritic cells to T cells. Journal of Virology, 78, 10848-10855.
52. Nair, M. P., Schwartz, S. A., Mahajan, S. D., Tsiao, C., Chawda, R. P., Whitney, R., et al. (2004). Drug abuse and neuropathogenesis of HIV infection: Role of DC-SIGN and IDO. Journal of Neuroimmunology, 157, 56-60.
53. Song, X. T., Evel-Kabler, K., Rollins, L., Aldrich, M., Gao, F., Huang, X. F., et al. (2006). An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Medicine, 3, e11.
54. Ebina, H., Aoki, J., Hatta, S., Yoshida, T., & Koyanagi, Y. (2004). Role of Nup98 in nuclear entry of human immunodeficiency virus type 1 cDNA. Microbes and Infection, 6, 715-724.
55. Fassati, A., Gorlich, D., Harrison, I., Zaytseva, L., & Mingot, J. M. (2003). Nuclear import of HIV-1 intracellular reverse transcription complexes is mediated by importin 7. The EMBO Journal, 22, 3675-3685.
56. Zielske S. P., & Stevenson M. (2005). Importin 7 may be dispensable for human immunodeficiency virus type 1 and simian immunodeficiency virus infection of primary macrophages. Journal of Virology, 79, 11541-11546.
57. Vandekerckhove, L., Christ, F., Van Maele, B., De Rijck, J., Gijsbers, R., Van den Haute, C., et al. (2006). Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus. Journal of Virology, 80, 1886-1896.
58. Llano, M., Saenz, D. T., Meehan, A., Wongthida, P., Peretz, M., Walker, W. H., et al. (2006). An essential role for LEDGF/p75 in HIV integration. Science, 314, 461-464.
59. Li, Z., Xiong, Y., Peng, Y., Pan, J., Chen, Y., Wu, X., et al. (2005). Specific inhibition of HIV-1 replication by short hairpin RNAs targeting human cyclin T1 without inducing apoptosis. FEBS Letters, 579, 3100-3106.
60. Ye, Y., De Leon, J., Yokoyama, N., Naidu, Y., & Camerini, D. (2005). DBR1 siRNA inhibition of HIV-1 replication. Retrovirology, 2, 63.
61. Kameoka, M., Nukuzuma, S., Itaya, A., Tanaka, Y., Ota, K., Inada, Y., et al. (2005). Poly(ADP-ribose)polymerase-1 is required for integration of the human immunodeficiency virus type 1 genome near centromeric alphoid DNA in human and murine cells. Biochemical and Biophysics Research Communications, 334, 412-417.
62. Ariumi, Y., Turelli, P., Masutani, M., & Trono, D. (2005). DNA damage sensors ATM, ATR, DNA-PKcs, and PARP-1 are dispensable for human immunodeficiency virus type 1 integration. Journal of Virology, 79, 2973-2978.
63. Komano, J., Miyauchi, K., Matsuda, Z., & Yamamoto, N. (2004). Inhibiting the Arp2/3 complex limits infection of both intracellular mature vaccinia virus and primate lentiviruses. Molecular Biology of the Cell, 15, 5197-5207.
64. Vazquez, N., Greenwell-Wild, T., Marinos, N. J., Swaim, W. D., Nares, S., Ott, D. E., et al. (2005). Human immunodeficiency virus type 1-induced macrophage gene expression includes the p21 gene, a target for viral regulation. Journal of Virology, 79, 4479-4491.
65. Hauber, I., Bevec, D., Heukeshoven, J., Kratzer, F., Horn, F., Choidas, A., et al. (2005). Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy. The Journal of Clinical Investigation, 115, 76-85.
66. Sanchez-Velar, N., Udofia, E. B., Yu, Z., & Zapp, M. L. (2004). hRIP, a cellular cofactor for Rev function, promotes release of HIV RNAs from the perinuclear region. Genes & Development, 18, 23-34.
67. Yu, Z., Sanchez-Velar, N., Catrina, I. E., Kittler, E. L., Udofia, E. B., & Zapp, M. L. (2005). The cellular HIV-1 Rev cofactor hRIP is required for viral replication. Proceedings of the National Academy of Science of the United States of America, 102, 4027-4032.
68. Fumagalli, S., Totty, N. F., Hsuan, J. J., & Courtneidge, S. A. (1994). A target for Src in mitosis. Nature, 368, 871-874.
69. Taylor, S. J., & Shalloway, D. (1994). An RNA-binding protein associated with Src through its SH2 and SH3 domains in mitosis. Nature, 368, 867-871.
70. Li, J., Liu, Y., Kim, B. O., & He, J. J. (2002). Direct participation of Sam68, the 68-kilodalton Src-associated protein in mitosis, in the CRM1-mediated Rev nuclear export pathway. Journal of Virology, 76, 8374-8382.
71. Modem, S., Badri, K. R., Holland, T. C., & Reddy, T. R. (2005). Sam68 is absolutely required for Rev function and HIV-1 production. Nucleic Acids Research, 33, 873-879.
72. Guo, F., Cen, S., Niu, M., Javanbakht, H., & Kleiman, L. (2003). Specific inhibition of the synthesis of human lysyl-tRNA synthetase results in decreases in tRNA(Lys) incorporation, tRNA(3)(Lys) annealing to viral RNA, and viral infectivity in human immunodeficiency virus type 1. Journal of Virology, 77, 9817-9822.
73. Murray, J. L., Mavrakis, M., McDonald, N. J., Yilla, M., Sheng, J., Bellini, W. J., et al. (2005). Rab9 GTPase is required for replication of human immunodeficiency virus type 1, filoviruses, and measles virus. Journal of Virology, 79, 11742-11751.
74. Garrus, J. E., von Schwedler, U. K., Pornillos, O. W., Morham, S. G., Zavitz, K. H., Wang, H. E., et al. (2001). Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell, 107, 55-65.
75. Ward, D. M., Vaughn, M. B., Shiflett, S. L., White, P. L., Pollock, A. L., Hill, J., et al. (2005). The role of LIP5 and CHMP5 in multivesicular body formation and HIV-1 budding in mammalian cells. The Journal of Biological Chemistry, 280, 10548-10555.
76. Muthumani, K., Choo, A. Y., Hwang, D. S., Premkumar, A., Dayes, N. S., Harris, C., et al. (2005). HIV-1 Nef-induced FasL induction and bystander killing requires p38 MAPK activation. Blood, 106, 2059-2068.
77. Liu, B., Sarkis, P. T., Luo, K., Yu, Y., & Yu, X. F. (2005). Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. Journal of Virology, 79, 9579-9587.
78. Wiznerowicz, M., Szulc, J., & Trono, D. (2006). Tuning silence: Conditional systems for RNA interference. Nature Methods, 3, 682-688.
79. Ping, Y. H., Chu, C. Y., Cao, H., Jacque, J. M., Stevenson, M., & Rana, T. M. (2004). Modulating HIV-1 replication by RNA interference directed against human transcription elongation factor SPT5. Retrovirology, 1, 46.
80. Chiu, Y. L., Cao, H., Jacque, J. M., Stevenson, M., & Rana, T. M. (2004). Inhibition of human immunodeficiency virus type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9/CyclinT1). Journal of Virology, 78, 2517-2529.
81. Ammosova, T., Berro, R., Kashanchi, F., & Nekhai, S. (2005). RNA interference directed to CDK2 inhibits HIV-1 transcription. Virology, 341, 171-178.
82. Kaldis, P., & Aleem, E. (2005). Cell cycle sibling rivalry: Cdc2 vs. Cdk2. Cell Cycle, 4, 1491-1494.
83. ter Brake, O., Konstantinova, P., Ceylan, M., & Berkhout, B. (2006). Silencing of HIV-1 with RNA interference: A multiple shRNA approach. Molecular Therapy, 14, 883-892.